Drug Profile
Doxorubicin liposomal - Tedec Meiji
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Tedec Meiji
- Developer Nonindustrial source; Tedec Meiji
- Class Anthracyclines; Antineoplastics; Antivirals; Cytostatic antibiotics; Doxorubicins; Hepatoprotectants; Small molecules
- Mechanism of Action Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in Spain (IV-infusion)
- 06 Mar 2000 Phase-I clinical trials for Solid tumours in Spain (IV-infusion)